M&A
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant
May 6, 2025Mergers and Acquisitions (OTC & VMS), Clayton, Clayton Dubilier & Rice (CD&R), Corporate, M&A, Opella, Sanofi, agreement
Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofi’s …
Funding overview for the pharmaceutical industry and outlook for 2020
March 2, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma
This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …
Pfizer to combine off-patent drug unit Upjohn with Mylan
July 30, 2019Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …
Takeda completes Shire acquisition
January 8, 2019Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma
Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …
AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T
January 8, 2019Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t
US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …
$400 billion in healthcare M&A deals expected for 2019
January 7, 2019Sales and Marketing Hong Kong, M&A, MA, biotech, deals pharma, law, mergers
The coming year is set to see mergers and acquisitions in the healthcare sector worth more than $400 billion, according …
Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn
December 19, 2018Business Services BMS, Japan, M&A, MA, Taisho, deal
Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …
Akorn CEO resigns after $4.3bn Fresenius deal falls through
December 10, 2018Sales and Marketing Akorn, CEO, Fresenius, M&A, MA, Raj Rai, court, generics
The CEO of American generics firm Akorn Inc has stepped down following a ruling from the Delaware Supreme Court declaring …
Takeda shareholders approve $62bn Shire acquisition
December 6, 2018Business Services Ireland, Japan, M&A, MA, Shire, Takeda, acquisition
Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc. The …
Novartis denies potential split with Sandoz
November 15, 2018Business Services, Manufacturing and Production Business, M&A, MA, Novartis, Sandoz, acquisition, mergers
Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …
Scottish borders-based Ryboquinn acquires viral delivery comany Nanogenics
July 20, 2018Medical Communications M&A, MA, Scotland, acquisitions, gene therapy, nanogenics, ryboquinn
The Scottish biotech company Ryboquinn has acquired English partner Nanogenics Solutions in a deal worth £4.45 million. The Selkirk-based firm …
Allergan bolsters skincare portfolio with Elastagen acquisition for $95 million
February 7, 2018Research and Development, Sales and Marketing Allergan, Elastagen, M&A, MA, pharma
Pharma’s M&A train keeps on going as news breaks that Allergan has picked up University of Sydney spin-off Elastagen for …
Rapidly-growing Nektar Therapeutics reportedly considering sale of its business
February 5, 2018Manufacturing and Production, Sales and Marketing M&A, MA, Nektar, Nektar Therapeutics, acquisition, pharma
After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 …
Seven pharma trends for 2018
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
Pharmafile.com looks ahead to signpost what we expect will be the key industry trends through the course of 2018.The value of …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
